INVO vs. AVGR, PAVM, SSKN, NXGL, PSTV, GCTK, PETV, BTCY, NURO, and INBS
Should you be buying INVO Bioscience stock or one of its competitors? The main competitors of INVO Bioscience include Avinger (AVGR), PAVmed (PAVM), STRATA Skin Sciences (SSKN), NEXGEL (NXGL), Plus Therapeutics (PSTV), GlucoTrack (GCTK), PetVivo (PETV), Biotricity (BTCY), NeuroMetrix (NURO), and Intelligent Bio Solutions (INBS). These companies are all part of the "surgical & medical instruments" industry.
INVO Bioscience (NASDAQ:INVO) and Avinger (NASDAQ:AVGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations.
INVO Bioscience has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Avinger has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.
In the previous week, INVO Bioscience and INVO Bioscience both had 2 articles in the media. Avinger's average media sentiment score of 0.96 beat INVO Bioscience's score of 0.44 indicating that Avinger is being referred to more favorably in the news media.
Avinger has a net margin of -251.78% compared to INVO Bioscience's net margin of -459.42%.
INVO Bioscience has higher earnings, but lower revenue than Avinger.
Avinger has a consensus price target of $5.00, suggesting a potential upside of 133.10%. Given Avinger's higher possible upside, analysts clearly believe Avinger is more favorable than INVO Bioscience.
12.0% of INVO Bioscience shares are owned by institutional investors. Comparatively, 18.3% of Avinger shares are owned by institutional investors. 3.5% of INVO Bioscience shares are owned by insiders. Comparatively, 11.4% of Avinger shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Avinger received 386 more outperform votes than INVO Bioscience when rated by MarketBeat users. Likewise, 59.46% of users gave Avinger an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote.
Summary
Avinger beats INVO Bioscience on 9 of the 13 factors compared between the two stocks.
Get INVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for INVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
INVO Bioscience Competitors List
Related Companies and Tools
